BLA 125544 · Celltrion INC
Inflectra
Infliximab-Dyyb · Injection · Tumor Necrosis Factor Blocker
Last checked: Nov 20, 2026Latest source record: Sep 3, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Apr 5, 2016
Approved uses
2
Original approval plus efficacy supplements
Registered trials
379
125 Phase 3, 45 recruiting
FAERS reports
29,668
24,848 serious, 722 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS INFECTIONS and MALIGNANCY WARNING: SERIOUS INFECTIONS and MALIGNANCY See full prescribing information for complete boxed warning • Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis) and infections due to other opportunistic pathogens. ( 5.1 ) • Discontinue INFLECTRA if a patient develops a serious infection. • Perform test for latent TB; if positive, start treatment for TB prior to starting INFLECTRA. Monitor all patients for active TB during treatment, even if initial latent TB test is negative. ( 5.1 ) • Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including infliximab products. ( 5.2 ) • Postmarketing cases of fatal hepatosplenic T-cell...
What it is approved for
From the label in effect Oct 29, 2026.
INFLECTRA is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease ( 1.1 ): • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. Pediatric Crohn's Disease ( 1.2 ): • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. Ulcerative Colitis ( 1.3 ): • reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. Pediatric Ulcerative Colitis ( 1.4 ): • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. Rheumatoid Arthritis ( 1.5 ) in combination with methotrexate: • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease. Ankylosing Spondylitis ( 1.6 ): • reducing signs and symptoms in adult patients with active disease. Psoriatic Arthritis ( 1.7 ): • reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients. Plaque Psoriasis ( 1.8 ):...
Mechanism: Infliximab products neutralize the biological activity of TNFα by binding with high affinity to the soluble and transmembrane forms of TNFα and inhibit binding of TNFα with its receptors. Infliximab products do not neutralize TNFβ (lymphotoxin-α), a related cytokine that utilizes the same receptors as TNFα. Biological activities attributed to TNFα include: induction of proinflammatory cytokines such as interleukins (IL) 1 and 6, enhancement of leukocyte migration by increasing endothelial layer permeability and expression of adhesion molecules by endothelial cells and leukocytes, activation...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 18, 2019 Supplement 9 · Efficacy LetterLabel
- Apr 5, 2016 Original approval · Type 2 - New Active Ingredient Pediatric Statistical ReviewPediatric Medical ReviewPediatric Addendum
1 products under this application
- INFLECTRA · INFLIXIMAB-DYYB 100MG · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Infliximab" as an intervention, any sponsor and status, largest first.
- Treatments for COVID-19: Canadian Arm of the SOLIDARITY TrialPivotal-lookingStatus unknown
Sunnybrook Health Sciences CentreAcademic, hospital or other
NCT04330690 · 2,900 participants (planned) · Start Mar 18, 2020 · Primary completion Mar 10, 2024
Drug: Artesunate; Imatinib and 3 more · For: COVID-19
Sites: Calgary, Canada; Edmonton, Canada; Kamloops, Canada · 53 sites in all
- Immune Modulators for Treating COVID-19Pivotal-lookingCompleted
Daniel BenjaminAcademic, hospital or other
NCT04593940 · 1,971 participants · Start Oct 15, 2020 · Primary completion Jan 30, 2022
Drug: Infliximab; Abatacept and 2 more · For: Covid19
Sites: Phoenix, Arizona; Little Rock, Arkansas; La Jolla, California · 91 sites in all
- Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF TherapyPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT00124982 · 1,286 participants · Start Apr 2005 · Primary completion Aug 2009
Drug: Abatacept; Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD) and 1 more · For: Rheumatoid Arthritis
Sites: Birmingham, Alabama; Huntsville, Alabama; Paradise Valley, Arizona · 148 sites in all
- Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's DiseaseActive, not recruiting
Connecticut Children's Medical CenterAcademic, hospital or other
NCT05781152 · 1,270 participants · Start Jun 10, 2023 · Primary completion Jul 1, 2028
Drug: Anti-TNF therapy · For: Crohn Disease
Sites: Phoenix, Arizona; Los Angeles, California; San Diego, California · 26 sites in all
- Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological ImmunotherapieRecruiting
IsalaAcademic, hospital or other
NCT06031233 · 1,082 participants (planned) · Start Sep 1, 2023 · Primary completion Jul 2028
Drug: Nivolumab; Pembrolizumab and 9 more · For: Oncology; Infusion Reaction
Sites: Zwolle, Netherlands
- Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)Pivotal-lookingCompleted
AbbottIndustry
NCT00338650 · 1,000 participants · Start Jun 2006
Drug: adalimumab · For: Crohn's Disease
Sites: Birmingham, Alabama; Jonesboro, Arkansas; Little Rock, Arkansas · 97 sites in all
- HLADQA1*05 Genotype and the Efficacy of Treatment With Infliximab in Chinese Population Crohn's DiseasePivotal-lookingStatus unknown
Sixth Affiliated Hospital, Sun Yat-sen UniversityAcademic, hospital or other
NCT05813860 · 976 participants (planned) · Start Apr 30, 2023 · Primary completion May 31, 2026
Drug: Azathioprine; Infliximab · For: Crohn Disease; Infliximab
- The Effects of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis (Study P04271AM2)(COMPLETED)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00251641 · 868 participants · Start Sep 1, 2005 · Primary completion Jun 1, 2008
Drug: infliximab; methotrexate · For: Psoriasis
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use15,555
- condition aggravated10,827
- intentional product use issue8,399
- inappropriate schedule of product administration7,041
- arthralgia5,039
- drug ineffective3,658
- fatigue3,494
- weight increased3,200
- weight decreased3,079
- malaise2,963
- headache2,464
- nausea2,417
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 7 |
| 2016 | 168 |
| 2017 | 1,138 |
| 2018 | 2,497 |
| 2019 | 1,612 |
| 2020 | 2,604 |
| 2021 | 3,484 |
| 2022 | 4,878 |
| 2023 | 4,251 |
| 2024 | 4,072 |
| 2025 | 2,706 |
| 2026 | 2,251 |
Recalls
1 FDA enforcement reports for this application.
Jan 17, 2025 · Class II · Ongoing
cGMP Deviations: Product intended for quarantine was inadvertently distributed.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Inflectra (Infliximab-Dyyb)
2024 spending
$37.7M
Beneficiaries
1,412
7,072 claims
Per beneficiary
$26,691
$737.48 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $5,625,504 |
| 2021 | $10,447,840 |
| 2022 | $23,565,720 |
| 2023 | $32,372,830 |
| 2024 | $37,687,135 |
Part B: Inflectra (Infliximab-Dyyb) · HCPCS Q5103
2024 spending
$21.1M
Beneficiaries
6,150
31,609 claims
Per beneficiary
$3,430
2024 ASP limit $12.42 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $71,265,191 |
| 2021 | $71,993,955 |
| 2022 | $73,696,298 |
| 2023 | $34,946,163 |
| 2024 | $21,096,945 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network meta-analysis of randomized clinical trials.
Spencer RK, Jin JQ, Elhage KG, et al. · J Am Acad Dermatol 2023 · Letter, Network Meta-Analysis
- Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
Singh S, Murad MH, Fumery M, et al. · Lancet Gastroenterol Hepatol 2021 · Comparative Study, Research Support, N.I.H., Extramural
- Infliximab versus Cyclophosphamide for Severe Behçet's Syndrome.
Saadoun D, Maalouf G, Vieira M, et al. · NEJM Evid 2024 · Clinical Trial, Phase II, Comparative Study
- Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn's disease: systematic review and network meta-analysis.
Barberio B, Gracie DJ, Black CJ, et al. · Gut 2023 · Systematic Review, Network Meta-Analysis
- Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial.
Ponsioen CY, de Groof EJ, Eshuis EJ, et al. · Lancet Gastroenterol Hepatol 2017 · Comparative Study, Multicenter Study
- Infliximab for induction and maintenance therapy for ulcerative colitis.
Rutgeerts P, Sandborn WJ, Feagan BG, et al. · N Engl J Med 2005 · Multicenter Study, Randomized Controlled Trial
Sponsor: Celltrion INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.